Effects of heparin on liver fibrosis in patients with chronic hepatitis B

doi:10.3748/wjg.v9.i7.1611

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3547)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-8) series, Tables (1-2) series.

Item

Count

PDF

446

HTML

2684

Figures (1-8)

215

Tables (1-2)

202

Sum=3547

Jul 15, 2003 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (35)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Jul 15, 2003; 9(7): 1611-1614
Published online Jul 15, 2003. doi: 10.3748/wjg.v9.i7.1611

Table 1 Treatment regimes in group A and B

Group	n	Treatment regime
A	18	regular treatment(GIK, diamnonium glycyrrhizinate injection, potassium magnesium aspartate, et al)
B	34	regular treatment and heparin(25mg, iv, bid) or low molecular weight heparin(6400IU, iH, qd)

Note: In group B, 18 cases were treated with heparin and 16 with low molecular weight heparin (LMWH). The LMWH was FLUX manufactured by ALFA WASSERMANN S.P.A (Italy).

Citation: Shi J, Hao JH, Ren WH, Zhu JR. Effects of heparin on liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2003; 9(7): 1611-1614
URL: https://www.wjgnet.com/1007-9327/full/v9/i7/1611.htm
DOI: https://dx.doi.org/10.3748/wjg.v9.i7.1611